Aardvark Therapeutics AARD
NASDAQ AARD
$1.59 +0.22 (+16.06%)
At close: Nov 11, 2026 · 4:00 PM EST

Aardvark Therapeutics (AARD) Return on Equity [ROE] (2025 - 2026)

Updated

Aardvark Therapeutics (AARD) recorded Return on Equity [ROE] of -86.41% in Q2 2026, down 61.04 percentage points from -25.37% a year earlier and down 14.24 percentage points from the prior quarter.

Analysis

Aardvark Therapeutics (AARD) Return on Equity [ROE] (2025 - 2026) Analysis & Trends

For FY2025, Aardvark Therapeutics reported Return on Equity [ROE] of -221.53%.

  • Per Business Quant, the preceding three quarters came in at -72.17% (Q1 2026), -50.29% (Q4 2025) and -37.59% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 19.33%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.63%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 21.60%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 72.13%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -31.17%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.66%
10 Aardvark Therapeutics 29.98 Mn -43.92 Mn - -86.39%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -86.39%
Mar 31, 2026 -72.20%
Dec 31, 2025 -50.22%
Sep 30, 2025 -37.55%
Jun 30, 2025 -25.48%
Mar 31, 2025 -57.63%
API Access

Aardvark Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=AARD&period=max&api_key=YOUR_API_KEY